Cartesian Therapeutics Announces New Employment Inducement Grants
05 Février 2024 - 10:05PM
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a
clinical-stage biotechnology company developing mRNA cell therapies
for the treatment of autoimmune diseases, today announced the
granting of inducement awards to five new employees. On February 1,
2024, the Company issued to each of these employees an option to
purchase shares of the Company’s common stock with a per share
exercise price of $0.75, the closing trading price of the Company’s
common stock on the Nasdaq Global Market on the date of grant. The
options are exercisable for an aggregate of 708,546 shares of the
Company’s common stock. Each of the five options was granted
pursuant to the Company’s 2018 Employment Inducement Incentive
Award Plan and was approved by the Company’s board of directors.
The options each vest as to 25% on February 1, 2025, and then in
three equal annual installments thereafter such that the options
will be fully vested on February 1, 2028. Each of the options has a
ten-year term. The options were granted under Rule 5365(c)(4) of
the Nasdaq Listing Rules as inducements material to each employee’s
entry into employment with the Company.
About Cartesian
Therapeutics
Cartesian Therapeutics is a clinical-stage
company developing mRNA cell therapies for the treatment of
autoimmune diseases. The Company’s lead asset, Descartes-08, is a
potential first-in-class mRNA CAR-T in Phase 2b clinical
development for patients with generalized myasthenia gravis.
Additional Phase 2 studies are planned in systemic lupus
erythematosus under an allowed IND, as well as basket trials in
additional autoimmune indications. The Company’s clinical-stage
pipeline also includes Descartes-15, a next-generation, autologous
anti-BCMA mRNA CAR-T. Cartesian operates a wholly owned,
state-of-the-art cGMP manufacturing facility in Gaithersburg,
MD.
Contact Information:Investor
Relations:Melissa ForstArgot
Partnerscartesian@argotpartners.com
Media:David RosenArgot
Partnerscartesian@argotpartners.com
Cartesian Therapeutics (NASDAQ:RNAC)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Cartesian Therapeutics (NASDAQ:RNAC)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024